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ORIGINAL ARTICLE
Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to
westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginter-
feron α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans.
Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-
2a (180 µg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 µg/
week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55).
Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%;
non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was
32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR
regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was
significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No
difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not
change based on genotype.
Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains
SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as
efficacious as a standard dose. (Korean J Intern Med 2009;24:203-211)
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INTRODUCTION
Combination therapy with peginterferon and ribavirin
is the treatment of choice for patients with chronic
hepatitis C virus (HCV) infection [1-3]. In westerns, this
therapy produces a sustained virologic response (SVR) in
approximately 40-45% of patients with HCV genotype 1
and 80% of patients with genotype non-1. 
A previous report of Korean patients [4] showed efficacy
for combination therapy comparable to that in studies in
Western countries. In that report [4], laboratory abnor-
malities including neutropenia, anemia, and other adverse
events such as flu-like symptoms were common events, as
with non-Asian patients. Dose modification was performed
in 39% (29/75) of patients without producing a significant
reduction in SVR. Moreover, no difference was observed
in SVR between those who received 50, 75, and 100% of
the suggested peginterferon dose. 
The frequency of adverse events in combination therapy
is relatively high (20-64%) [1-3,5-7], and dose reductions
of either peginterferon or ribavirin were required in 32-
42% of patients who experienced adverse events [1-3, 5-7].
Patients experienced substantial reductions in SVR [8-9]
as a result of the dose reduction. Because body weight is
generally lower in Asian patients than in non-Asians, using
the same dose of peginterferon in Korean patients could
lead to a more frequent dose reduction and subsequently
lead to a greater impairment in SVR than in non-Asian
patients, although peginterferon α-2a need not be dosed
by body weight [10]. The aim of this study was to evaluate
the frequency of dose modification and its effect on viro-
logic response in Korean hepatitis C patients in a routine
clinical setting.
METHODS
This study stemmed from the Pegasys project, which is
a multi-center, open-label expanded-access program for
peginterferon α-2a (Pegasys®, Roche, Swiss) in combination
with ribavirin (Viramid®, Ilsung, Korea) in Korean patients
with chronic hepatitis C. The study included six clinical
centers in Korea, all of which were tertiary university
hospitals. The study protocol was approved by the institu-
tional review board of each participating institution, and
written consent was obtained from all patients.
Patient population
The inclusion criteria for this study were as follows: men
and women aged >18 years with serologically proven
chronic hepatitis C. In addition, the patients must have
had detectable HCV RNA, elevated alanine aminotrans-
ferase (ALT), a liver biopsy consistent with chronic hepatitis
C with or without cirrhosis, and compensated liver disease
(Child-Pugh grade A). Patients with other forms of liver
disease, such as active hepatitis A virus or hepatitis B virus
infection, hepatocellular carcinoma, hemochromatosis,
autoimmune hepatitis (antinuclear antibody positive),
metabolic liver disease, alcoholic liver disease, and toxin
exposures were excluded. Patients with human immun-
odeficiency virus, anemia, pre-existing severe depression
or other psychiatric disease, seizure disorders, immun-
ologically mediated disease, such as lupus erythematosus,
inflammatory bowel disease, rheumatoid arthritis, signifi-
cant cardiac disease, chronic pulmonary disease with
functional limitation, renal disease, severe retinopathy,
major organ transplantation with an existing functional
graft, thyroid disease poorly controlled on prescribed
medications, and drug abuse (including excessive alcohol
consumption) were also excluded.
Treatment protocol
Patients with genotype 1 were treated with peginterferon
α-2a 180 µg/week and a daily ribavirin dose of 1,000 mg
(weight <75 kg) or 1,200 mg (weight ≥75 kg) for 48 weeks.
Alternatively, patients with genotype non-1 were treated
with peginterferon α-2a 180 µg/week and a daily ribavirin
dose of 800 mg for 24 weeks. Patients with no early viro-
logic response (EVR) at week 12 were recommended to
stop treatment at that time. However, continued treatment
with peginterferon α-2a may be justified in individual
patients, particularly those who have accompanying
cirrhosis and could benefit from an improvement in
histology. Complete blood cell counts and blood chemistry
were monitored at screening and at weeks 2, 4, 8, 16, and
24 for both genotypes and at weeks 32 and 48 for genotype
1 only. In addition, HCV RNA was checked at weeks 12,
24, and 48 for both genotypes and at week 72 for genotype
1 only. 
Definitions of response
EVR was defined as the absence of detectable serum
HCV-RNA by a Roche AMPLICOR HCV Test v2.0 (Roche
Molecular Systems; Pleasanton, CA, USA) (<50 IU/mL)
or a decrease in HCV-RNA of at least log 2 after 12 weeks
of treatment. SVR was defined as the absence of detectable
serum HCV RNA after 24 weeks of treatment.
Dose modification
Dose modification included a dose reduction or prema-
ture discontinuation of treatment. The peginterferon α-2a
dose was reduced stepwise from 180 to 135, to 90, and
then to 45 µg/week if the absolute neutrophil count (ANC)
fell below 750 cells/mm3. For patients with an ANC below
500 cells/mm3, treatment was suspended until ANC
values returned to more than 1,000 cells/mm3. A dose
reduction of peginterferon α-2a to 90 µg was recom-
mended if the platelet count fell below 50,000 cells/mm3.
Cessation of therapy was recommended when the platelet
count decreased to levels below 25,000 cells/mm3. The
dose was initially reduced to 90 µg if ALT progressively
increased above baseline values. The normal upper limit
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for ALT was defined as 45 U/mL. When an increase in
ALT levels was progressive, despite dose reduction, or was
accompanied by increased bilirubin or evidence of hepatic
decompensation, therapy was discontinued. 
The daily ribavirin dose was reduced by 200 mg when a
patient without significant cardiovascular disease
experienced a drop in hemoglobin to 8.5-10 g/dL or a
patient with stable cardiovascular disease experienced a
drop in hemoglobin by >2 g/dL during any 4 weeks of
treatment. Ribavirin was discontinued if a patient without
significant cardiovascular disease experienced a decrease
in hemoglobin to a level confirmed to be below 8.5 g/dL or
if a patient with stable cardiovascular disease maintained
a hemoglobin value <12 g/dL despite 4 weeks on a reduced
dose of 600 mg. Further dose modification of one or both
drugs for other adverse events was based on side-effect
Kwon JH, et al. Dose reduction in the treatment of hepatitis C    205
Table 1. Baseline characteristics of the study population according to the dose modification
Demographics Dose-modification No dose-modification Total p value
(n=48, 52.2%) (n=44, 47.8%) (n=92)
Age, years 53.1±9.9 47.0±10.6 50.2±10.6 0.005†
Male/female 31/17 33/11 64/28 0.365‡
Body weight, kg 66.4±9.3 68.9±10.6 67.6±10.0 0.249†
Genotype 0.327‡
Genotype 1 31 (64.6) 24 (54.5) 55 (59.8)
Genotype non-1 17 (35.4) 20 (45.5) 37 (40.2)
ALT, IU/L 134.9±91.8 134.0±110.6 134.5±100.7 0.968†
HCV RNA, ×105 IU /mL 7.0±6.3 8.7±7.9 7.8±7.1 0.259†
Cirrhosis in histology 6 (12.5) 3 (6.8) 9 (9.8) 0.691‡
Retreatment 0.577‡
Naïve 28 (58.3) 23 (52.3) 51 (55.4)
Non-naïve (nonresponder/relapser) 20 (16/4) 21 (15/6) 41 (30/11)
Values are number (percentage) or mean±SD
ALT, alanine aminotransferase; HCV, hepatitis C virus. 
† Analysis of variance.
‡ Chi-square test.
Figure 1. Patient flow diagram. Three patients in genotype non-1 and four patients in genotype 1 were excluded from the study due to
EVR failure. One patient with genotype 1 was excluded due to adverse events at week 27, and two patients were lost to follow-up after
the end of treatment before SVR was checked. EVR, early virologic response; SVR, sustained virologic response.
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severity. The dose of ribavirin was increased if the
hemoglobin increased above 10 g/dL or if the adverse event
resolved. In general, we adjusted and maximized ribavirin
doses according to tolerability [11]. 
The treatment period for any patient was not extended
beyond that specified for his/her assigned treatment
group (i.e., 24 weeks for genotype non-1 and 48 weeks for
genotype 1).
Dose counting
The doses of each drug taken by each patient were
measured during the course of the study and evaluated by
reviewing the case report form. The amounts of both
medications taken by each patient during the first 12
weeks of treatment were expressed as a percentage of
the total prescribed dose. The percentage of the total dose
of each drug received during the entire treatment period
was calculated in a similar fashion. 
Statistical analysis
The statistical analysis for the virologic response was
performed using an intention-to-treat analysis. Basal
characteristics were expressed as means±2SD or the
absolute number and percentage of patients. ANOVA,
Pearson chi-square test, or Fisher’s exact test were used to
compare means or the proportion of basal characteristics
between two or more groups. The trends within each dose
category were determined with a linear-by-linear associ-
ation. The factors affecting SVR were analyzed by logistic
regression. All analyses were two-tailed with an α of 0.05.
All calculations were performed with SPSS version 14
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patient population
A total of 92 patients were enrolled in this study (Table
1). Thirty-seven patients were infected with genotype non-
1 and 55 patients with genotype 1 hepatitis C. The mean
age of the patients was 50.2 years, and the sex ratio
(male/female) was 64/28. The mean body weight was
67.6 kg, and the mean serum ALT and HCV RNA were
134.5 IU/L and 7.8 × 105 IU/mL, respectively. All patients
underwent a liver biopsy, and the results of the histologic
examinations revealed a 9.8% occurrence of liver cirrhosis.
The percentage of naïve patients was 55.4% (51/92), and
the proportions of naïve patients in genotype 1 and non-1
were 47.3% and 67.6%, respectively (not shown in Table
1). Among non-naïve patients, 30 were non-responders
and the remaining 11 patients had relapsed. Non-naïve
patients had been injected with conventional interferon.
After checking the EVR of all patients at week 12, we
excluded three patients in genotype non-1 and four
patients in genotype 1 due to EVR failure. One patient
with genotype 1 was excluded due to severe anemia and
neutropenia at week 27. Two patients with genotype 1
were lost from follow-up after treatment week 48 (Fig. 1).
Two patients with genotype non-1 discontinued the
ribavirin (one each at weeks 6 and 8), but maintained the
peginterferon alone over the entire treatment period (not
shown in the Fig. 1).
A dose modification was performed in 32.6% of patients
within the first 12 weeks of treatment and in 52.2% of
patients during the entire treatment period (Table 1). The
mean age of patients in the dose-modification group was
significantly higher than that in the no dose-modification
group. However, in cases of genotype 1 patients who should
have received more ribavirin than did genotype non-1
patients, no significant difference was found in the dose-
modification rate compared to genotype non-1 patients.
Forty-one of the 55 patients (74.5%) in the genotype 1
group received a 1,000 mg dose of ribavirin due to low
weight (<75 kg). Among the genotype 1 patients, the rate
of dose modification was not different between 1,000 mg
and 1,200 mg users (59.5% vs. 50.0%, p=0.579). The
fraction of naïve and non-naïve patients, proportion with
cirrhosis, sex ratio, body weight, mean serum ALT level,
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Table 2. Virologic response based on genotype and naïve or non-naïve patients
Total Genotype† Naïve or non-naïve†
Type 1 Non-1 p * Naïve Non-naïve p *
EVR 71/92 (77) 41/55 (75) 30/37 (81) 0.464 45/51 (88) 26/41 (63) 0.005
SVR 61/92 (66) 31/55 (56) 30/37 (81) 0.041 45/51 (88) 16/41 (39) <0.001
Values are number (percentage).
EVR, early virologic response; SVR, sustained virologic response. 
*Chi-square test for comparison between two groups. 
† Intention to treatment analysis.
and HCV RNA were not different between the dose-
modification and no dose-modification groups.
Virologic response rates according to dose
modification
The EVR and SVR of all patients evaluated were 77%
and 66%, respectively (Table 2). EVR was not significantly
different between the HCV genotypes. The SVR of genotype
non-1 patients was significantly higher than that of the
genotype 1 group (81% vs. 56%, p=0.041). The EVR and
SVR of the naïve patients were significantly higher than
were those of the non-naïve patients (88% vs. 63%,
p=0.005 and 88% vs. 39%, p<0.001, respectively). 
However, no difference was found in EVR and SVR
regardless of dose modification and regardless of whether
the modification occurred within the first 12 weeks or at
any time during the treatment period. Also, this result
held regardless of genotype and of whether the patient
was drug-naïve. Similarly, EVR did not significantly
change after dose modifications in the first 12 weeks in
either genotype group or in the naïve and non-naïve groups
(Table 3). 
The effect of reducing peginterferon or ribavirin
dose on SVR during the entire treatment period
We analyzed the impact of reducing the peginterferon
dose independent of ribavirin. The effect of reducing the
dose of one or both drugs on SVR is described in Table 4.
SVR was not adversely affected when the dose of ribavirin
was reduced from 98-100% to ≤60% (p=0.832) in patients
who received a full dose of peginterferon. A comparison of
the SVR from the four peginterferon groups revealed a
strong relationship between reducing the peginterferon
dose and impaired SVR (p=0.050). A comparison of the
SVR from the four ribavirin groups revealed no relationship
between reductions in the ribavirin dose and impaired
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Table 3. Virologic response according to the drug dose modification
EVR rate (%) SVR rate (%) SVR rate (%)
by modification by modification by modification during
within 12 weeks † within 12 weeks‡ the whole treatment period‡
Yes No p * Yes No p * Yes No p *
Genotype non-1 10/12 (83) 20/25 (80) 1.000 10/11 (91) 20/23 (87) 1.000 13/14 (93) 17/20 (85) 0.627
Genotype 1 15/18 (83) 26/37 (70) 0.346 8/14 (57) 23/34 (68) 0.489 15/24 (63) 16/24 (67) 0.763
Naïve 16/19 (84) 29/32 (91) 0.659 16/18 (89) 29/31 (94) 0.618 23/26 (86) 22/23 (96) 0.612
Non-naïve 9/11 (82) 17/30 (57) 0.168 2/7 (29) 14/26 (54) 0.398 5/12 (42) 11/21 (52) 0.721
Total 25/30 (83) 46/62 (74) 0.328 18/25 (72) 43/57 (75) 0.743 28/38 (74) 33/44 (75) 0.892
Values are number (percentage).
EVR, early virologic response; SVR, sustained virologic response. 
* Chi-square or Fisher’s exact test for comparison between two groups. 
† Intention to treatment analysis.
‡ Per protocol analysis.
Table 4. Effect of reducing peginterferon or ribavirin doses during the entire treatment period on SVR
Peginterferon α-2a *
≥98% ≥80% ≥60% <60% Total
Ribavirin †
≥98% 33/42 (78.6) 3/3 (100.0) 3/4 (75.0) 3/5 (60.0) 42/54 (77.8)
≥80% 8/10 (80.0) 1/1 (100.0) 0/1 (0) 1/1 (100.0) 10/13 (76.9)
≥60% 4/5 (80.0) 0/4 (0) 1/2 (50.0) 5/11 (45.5)
<60% 1/1 (100.0) 2/2 (100.0) 1/1 (100.0) 4/4 (100.0)
Total 46/58 (79.3) 6/6 (100.0) 4/10 (40.0) 5/8 (62.5) 61/82 (74.4)
Values represent the number of patients with SVR among patients using each dose of peginterferon or ribavirin, and the percentage is
shown in parentheses. 
*p=0.050 for the comparison of the 4 peginterferon groups (linear-by-linear association), p=0.007 for the comparison of the 2
peginterferon groups divided by 80% (chi-square test).
† p=0.488 for the comparison of the 4 ribavirin groups (linear-by-linear association), p=0.158 for the comparison of the 2 ribavirin groups
divided by 80% (chi-square test).
SVR (p=0.488). 
We separated and regrouped the four peginterferon
groups into two groups on either side of the 80% peginter-
feron dose level and found that SVR was significantly
higher for those using ≥80% of the peginterferon dose
compared to those using <80% of the peginterferon dose
(p=0.007). Using the same method and regrouping the
four ribavirin groups on either side of the 80% ribavirin
dose revealed no significant difference in SVR between the
two ribavirin-dose groups (p=0.158). We also compared
the effect of using ≥80% of the peginterferon dose
between the genotype 1 and non-1 groups and between the
naïve and non-naïve patients. Results indicated that SVR
for those using ≥80% of the peginterferon dose was
significantly higher than that for those using <80% of the
peginterferon dose in the genotype 1, naïve, and non-naïve
groups, but it was not significantly different in the genotype
non-1 group. No difference was found in SVR in either
genotype group or in the naïve group based on using 80%≥
or <80% of the ribavirin dose. In the non-naïve patients,
SVR was higher for those using ≥80% of the ribavirin dose
than for those using <80% of the dose (p=0.044). However,
the number of patients using <80% of the ribavirin dose
was too small to analyze. 
We also analyzed several SVR predictors, adjusted for
age and body weight in logistic regression models (Table
5). The results indicated that using more than 80% of
the peginterferon dose was a significant predictor (relative
risk [RR], 4.446; confidence interval [CI], 1.437-13.759)
of SVR. Other variables including genotype non-1, no
cirrhosis in histology, drug naïve, and low HCV RNA level
were also significant predictors of SVR.
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Table 5. Predictors of sustained virologic response after adjusting for age and body weight
Predictor Relative risk 95% CI p *
Female 1.123 0.288-4.386 0.867
Genotype non-1 4.148 1.245-13.817 0.021
Non-cirrhotic histology 7.576 1.455-39.451 0.016
Naïve patient 12.183 3.523-42.135 <0.001
Low level of HCV RNA† 4.562 1.556-13.376 0.006
PEG dose > 80% ‡ 4.446 1.437-13.759 0.010
CI, confidence interva; HCV, hepatitis C virus; PEG, peginterferon. 
*Logistic regression. 
† Low viral load means ≤750,000 IU/mL of HCV RNA.
‡ Using more than 80% of the expected peginterferon dose during the entire treatment period.
Table 6. Adverse effects of peginterferon
Side effects Frequency No. of patients
with subsequent
dose modification
Laboratory abnormalities 31 (33%) 30
Neutropenia 28 (30%) 28
Anemia 1 (1%) 1
Thrombocytopenia 1 (1%) 1
Elevated ALT 1 (1%) 0
Adverse symptoms 12 (13%) 6
Myalgia 4 (4%) 1
Pruritis 2 (2%) 2
Abdominal pain 2 (2%) 1
Nausea 2 (2%) 1
Others 2 (2%) 1
ALT, alanine aminotransferase.
Table 7. Adverse effects of ribavirin
Side effects Frequency No. of patients
with subsequent
dose modification
Laboratory abnormalities 28 (30%) 26 
Neutropenia 1 (1%) 1
Anemia 27 (29%) 25
Thrombocytopenia 0 0
Elevated ALT 0 0
Adverse symptoms 12 (13%) 5 
Myalgia 4 (4%) 2
Pruritis 2 (2%) 1
Abdominal pain 2 (2%) 0
Nausea 2 (2%) 2
Others 2 (2%) 0
ALT, alanine aminotransferase.
Side effects
The side effects of peginterferon and ribavirin are
presented in Tables 6 and 7. The main causes for dose
modification in the peginterferon and ribavirin groups
were neutropenia and anemia, respectively. Among the
patients who showed laboratory abnormalities, over 90%
reduced the dose or stopped taking the drug. We found
that 12 patients in both the peginterferon and ribavirin
groups complained of adverse events such as myalgia and
pruritis, among others. Among the patients who experi-
enced adverse events, 50% reduced the dose or stopped
taking the drugs.
DISCUSSION
This study analyzed the effect of peginterferon and
ribavirin dose modification on SVR in Korean patients
with chronic hepatitis C. In another Korean report [4],
Korean patients were similar to non-Asian patients in
their virologic response to combination therapy [1-3];
however, the doses were modified in over half of the
patients during the treatment period. 
The rate of dose modification appears to be higher in
Asian patients than in non-Asian patients. In Western
studies, dose modification and premature discontinuation
for adverse events were found in 32 and 10% of patients,
respectively [1,2]. In Japanese and Taiwanese studies, 56
and 46% of patients, respectively, required a dose modifi-
cation [12,13]. Considering the basal characteristics of
enrolled patients, we found a difference in age and body
weight between Asians and non-Asians. In Japan, patients
infected with chronic hepatitis C who are currently being
treated with interferon are 10-15 years older on average
than are corresponding patients in the United States,
where patients treated with antiviral therapy tend to
average 45 years of age [12]. In that study, dose modifi-
cation was more frequent in older groups, occurring in 38,
42, and 77% of the <50, 50-59, and ≥60 year-old groups,
respectively (p<0.001). On average, patients in present
study were 5 years older than were the Western patients,
and the mean age in the dose modification group was
higher than that in the no dose modification group (p=
0.005). This suggests that age is a significant factor for
impaired adherence and affects the safety of combination
therapy. Furthermore, the body weight of patients in the
Asian studies is lower than that of patients in the Western
studies (about 65 vs. 80 kg) [1-4, 12,13]. Although pegin-
terferon α-2a dose need not be altered for body weight
[10], the lower body weight in Asian patients is believed to
contribute to a higher dose modification rate for pegin-
terferon α-2a. 
We found that simple dose modification and the timing
of dose modification had no significant effect on EVR and
SVR. Although one limitation of this study is the hetero-
geneity of the patient population with regard to genotypes
and prior drug experience, this result was observed for all
subgroups. We also found that using ≥80% dose of pegin-
terferon was a significantly affected SVR, despite
variations in the ribavirin dose. Moreover, this factor was
significant in all subgroups except for the genotype non-1
group. This result is consistent with a previous report
indicating that genotype non-1 is a good prognostic factor
for achieving SVR. Nevertheless, our results suggest that
more than 144 µg/week (80% of 180 µg/week) of pegin-
terferon α-2a during the entire treatment period may be
the optimal dose for Korean patients.  
In contrast to our results, several studies have suggested
that reducing the dose, especially in the first 12 weeks of
treatment, is associated with a decline in SVR [8-9,12,14-
16]. In the HALT-C trial cohort, the SVR of patients
dropped from 17 to 7% when the peginterferon dose was
reduced during the initial 20 weeks of therapy [14]. A
reduction from ≥80% to ≤60% of the planned total dose
during the first 20 weeks of treatment was associated with
a decline in SVR from 20-21% to 11-13% [9]. However,
these studies were based on non-responder retreatments
or peginterferon α-2b (1.5 µg/kg/week). Another study
found no significant relationship between the timing of
dose reduction and impaired SVR, similar to our study
[8]. In the present study, most patients who reduced the
dose within the first 12 weeks did not discontinue the
drugs; rather, the drug doses were adjusted and maximized
according to tolerability [11]. This may be the reason that
reducing the drug dose had no effect on SVR within the
first 12 weeks. 
Reducing or discontinuing ribavirin prematurely was
associated with a marked drop in SVR [14-15,17-19].
However, in a large long-term trial from the HALT-C trial
cohort [14], it was suggested that reducing the ribavirin
dose appeared to have little impact on SVR if patients did
not discontinue ribavirin and remained on full-dose
peginterferon. This is consistent with our result, although
we could not analyze the effect on SVR of discontinuing
ribavirin. Considering the older age and lower body weight
among patients in the present study than among Western
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patients [1-3], a large number of patients could be
permitted the lower dose of ribavirin; thus, 75% of patients
could take more than 80% and most could take more than
60% of the ribavirin. This may be the reason that the
ribavirin dose had no significant effect on efficacy in our
study, as in other studies. Moreover, two patients with
genotype non-1 prematurely discontinued ribavirin at
weeks 6 and 8 but achieved EVR and SVR by maintaining
the full dose of peginterferon alone. Although further
study with a large, homogenous group is necessary, we
suggest that the effect of ribavirin on SVR was less
apparent than was that of peginterferon. 
Side effects, especially hematologic toxicity, accounted
for the vast majority of dose reductions [1,2]. Analysis of
basal characteristics that could lead to more side effects
showed that older age and lower body weight were more
significant factors than was the drug itself.
Several recent studies have examined whether the
treatment period can be shortened [20,21]. These studies
indicate that treatment duration for HCV genotype non-1
should be shortened to less than 24 weeks if the patient
achieves a rapid virologic response (RVR). In the present
study, we did not check RVR at week 4, but analyzed the
percentage of total prescribed dose and examined the
impact of reducing the peginterferon dose according to
the timing of dose modification instead of shortening the
treatment period based on RVR. 
In conclusion, the present analyses have enhanced our
understanding of how dose reduction can affect SVR in
Korean patients with chronic hepatitis C. We suggest that
using at least 80% (144 of 180 µg/week) of the pegin-
terferon α-2a during the entire treatment period not only
maintains SVR but also reduces side effects. In addition,
our results show that using a dose of ribavirin lower than
the standard dose may still be efficacious in Korean
patients. Further studies should be conducted in larger
populations with a homogeneous genotype to confirm
these results.
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